Company Focus
Biogen
Latest Biogen News
Biotechnology
US biotech major Biogen today announced the appointment of Tim Power as vice president, head of investor relations, effective immediately. 9 December 2024
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company focused on delivering innovative immunology therapeutics.
Latest News & Features of interest to Biogen
Biotechnology
New York pharma giant Bristol Myers Squibb is getting into Alzheimer’s in a big way, snapping up global rights to an antibody program from BioArctic. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Sweden-based biotech Hansa Biopharma has released promising full results from a Phase II study evaluating imlifidase, its IgG-cleaving enzyme, in severe Guillain-Barré syndrome (GBS). 18 December 2024
Biotechnology
Eli Lilly has announced that China’s National Medical Products Administration has approved Kisunla (donanemab-azbt) for certain adults with early Alzheimer’s disease. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Generics
Venture capital firm BC Partners has entered into an agreement under which the private equity business at Goldman Sachs Alternatives will acquire a majority stake in Netherlands-based Synthon, from funds advised by BC Partners. 17 December 2024
Pharmaceutical
Neurocrine Biosciences has secured US Food and Drug Administration approval for Crenessity (crinecerfont). 17 December 2024
Pharmaceutical
Belgian drugmaker UCB today announced the ORCHESTRA proof-of-concept study of minzasolmin - an investigational, oral small molecule, alpha-synuclein misfolding inhibitor - developed in partnership with Novartis for early Parkinson’s disease, did not meet its primary and secondary clinical endpoints. 17 December 2024
Biotechnology
US health technology assessor the Institute for Clinical and Economic Review (ICER) as released a Final Evidence Report assessing the comparative clinical effectiveness of French drugmaker Pierre Fabre’s tabelecleucel (tab-cel) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). 17 December 2024
Latest In Brief for Biogen
Biotechnology
The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD). 5 December 2024
Latest Relevant Ones To Watch News
Venture capital firm BC Partners has entered into an agreement under which the private equity business at Goldman Sachs Alternatives will acquire a majority stake in Netherlands-based Synthon, from funds advised by BC Partners. 17 December 2024
16 December 2024
16 December 2024
21 November 2024
12 November 2024
5 November 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze